Roche completes $4.3B purchase of Philadelphia gene therapy pioneer Spark Therapeutics

The Federal Trade Commission and European regulators cleared Roche's proposed $4.3 billion purchase of Spark Therapeutics, paving the way for its acquisition of the Philadelphia gene therapy pioneer to be completed Tuesday. Roche entered into an agreement to buy Spark (NASDAQ: ONCE) in February. Its tender offer to Spark shareholders, however, was extended 10 times to provide additional time for the Federal Trade Commission and the UK Competition and Markets Authority to complete their reviews…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news